" Defence Therapeutics (CSE:DTC) begins IND-enabling testing of Its AccuTOX lead compound against breast cancer

Defence Therapeutics (DTC) has begun its final step in GLP studies on its lead anti-cancer AccuTOXTM molecule at Eurofins Advinus Limited.

" Defence Therapeutics (CSE:DTC) Accum variants increases potency of T-Deruxtecan antibody-drug conjugate

Defence Therapeutics’ (DTC) is pleased to announce strong in vitro results of its AccumTM variants on the recent Enhertu®ADC owned by AstraZeneca and

" Defence Therapeutics (CSE:DTC) is preparing to initiate a Phase I trial for one of its leading AccuTOX candidates against breast cancer

Defence Therapeutics (DTC) will be completing all requirements needed to initiate a Phase I trial for one of its leading AccuTOX candidate against
Knight Therapeutics Inc. - Jody Engel, Country Manager Canada

" Knight Therapeutics (TSX:GUD) receives Health Canada approval for NERLYNX (Neratinib)

Health Canada has approved NERLYNX® (neratinib) for the treatment of metastatic HER2-overexpressed/amplified breast cancer.